{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T04:13:47Z","timestamp":1794456827442,"version":"4.9.1"},"reference-count":142,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have increasingly been the mainstay of treatment for numerous malignancies. However, due to their association with autoimmunity, ICIs have resulted in a variety of side effects that involve multiple organs including the endocrine system. In this review article, we describe our current understanding of the autoimmune endocrinopathies as a result of the use of ICIs. We will review the epidemiology, pathophysiology, clinical presentation, diagnosis, and management of the most commonly encountered endocrinopathies, including thyroiditis, hypophysitis, Type 1 diabetes, adrenalitis, and central diabetes insipidus.<\/jats:p>","DOI":"10.3389\/fendo.2023.1157805","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T08:28:56Z","timestamp":1683793736000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":56,"title":["Endocrine side effects of immune checkpoint inhibitors"],"prefix":"10.3389","volume":"14","author":[{"given":"Zulma","family":"Cardona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Sosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunandana","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12092091","article-title":"Immune-related uncommon adverse events in patients with cancer treated with immunotherapy","volume":"12","author":"Albarran-Artahona","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-Small-Cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced Non\u2012Small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.894015","article-title":"Insights into the host contribution of endocrine associated immune-related adverse events to immune checkpoint inhibition therapy","volume":"12","author":"Chye","year":"2022","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10010088","article-title":"Emerging therapies in pheochromocytoma and paraganglioma: immune checkpoint inhibitors in the starting blocks","volume":"10","author":"Fanciulli","year":"2020","journal-title":"J Clin Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01430","article-title":"PD-1 inhibitor immune-related adverse events in patients with preexisting endocrine autoimmunity","volume":"103","author":"Akturk","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124427","article-title":"Combination of ipilimumab and nivolumab in cancers: from clinical practice to ongoing clinical trials","volume":"21","author":"Kooshkaki","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01289-w","article-title":"Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation","volume":"23","author":"Kennedy","year":"2022","journal-title":"Nat Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13073-020-00756-z","article-title":"Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis","volume":"12","author":"Trzupek","year":"2020","journal-title":"Genome Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3746","article-title":"Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations","volume":"20","author":"Schubert","year":"2014","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1414576112","article-title":"CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement","volume":"112","author":"Wang","year":"2015","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3453","article-title":"PD-1 expression in head and neck squamous cell carcinomas derives primarily from functionally anergic CD4(+) TILs in the presence of PD-L1(+) TAMs","volume":"77","author":"Mattox","year":"2017","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139867","article-title":"PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy","volume":"10","author":"Sponaas","year":"2015","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31184","article-title":"Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells","volume":"182","author":"Grosso","year":"2009","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22105282","article-title":"LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems","volume":"117","author":"Grosso","year":"2007","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22105282","article-title":"Understanding LAG-3 signaling","volume":"22","author":"Chocarro","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112687","article-title":"Clinical presentation of immune-related endocrine adverse events during immune checkpoint inhibitor treatment","volume":"14","author":"Chieng","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.cgh.2020.01.033","article-title":"Management of patients with immune checkpoint inhibitor-induced enterocolitis: a systematic review","volume":"18","author":"Collins","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0174","article-title":"Diagnosis and management of hepatitis in patients on checkpoint blockade","volume":"23","author":"Reynolds","year":"2018","journal-title":"Oncologist"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.21037\/tlcr.2017.12.10","article-title":"Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis","volume":"6","author":"Hu","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000467","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","volume":"8","author":"Meraz-Mu\u00f1oz","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2021.01.001","article-title":"Ocular side effects of checkpoint inhibitors","volume":"66","author":"Alba-Linero","year":"2021","journal-title":"Surv Ophthalmol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.013","article-title":"Hematological immune related adverse events after treatment with immune checkpoint inhibitors","volume":"147","author":"Kramer","year":"2021","journal-title":"Eur J Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061308","article-title":"Neutrophil-to-Lymphocyte ratio predicts development of immune-related adverse events and outcomes from immune checkpoint blockade: a case-control study","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40842-018-0073-4","article-title":"Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports","volume":"5","author":"Tan","year":"2019","journal-title":"Clin Diabetes Endocrinol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13483","article-title":"Endocrinopathies with use of cancer immunotherapies","volume":"88","author":"Villa","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-017-0778-8","article-title":"Thyroid dysfunctions secondary to cancer immunotherapy","volume":"41","author":"Chalan","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0169","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis","volume":"181","author":"Albarel","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.aace.2020.11.003","article-title":"Pembrolizumab-associated hypoparathyroidism: a single case report","volume":"7","author":"Mahmood","year":"2021","journal-title":"AACE Clin Case Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002220","article-title":"Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology","volume":"9","author":"\u00d6zdemir","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1210\/js.2018-00366","article-title":"Immune checkpoint blockade anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome","volume":"3","author":"Lanzolla","year":"2019","journal-title":"J Endocr Soc"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-20-0123","article-title":"Diabetes insipidus secondary to nivolumab-induced neurohypophysitis and pituitary metastasis","volume":"2021","author":"Fosci","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-245846","article-title":"Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab","volume":"15","author":"Zand Irani","year":"2022","journal-title":"BMJ Case Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/js.2017-00414","article-title":"Two cases of atezolizumab-induced hypophysitis","volume":"2","author":"Kanie","year":"2018","journal-title":"J Endocr Soc"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-250696","article-title":"Thyroid storm induced by combined nivolumab and ipilimumab immunotherapy in advanced non-small cell lung cancer","volume":"15","author":"Kataoka","year":"2022","journal-title":"BMJ Case Rep"},{"key":"B46","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12902-022-01190-5","article-title":"Durvalumab-induced thyroiditis in a patient with non-small cell lung carcinoma: a case report and review of pathogenic mechanisms","volume":"22","author":"de Filette","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"B47","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1634\/theoncologist.2019-0555","article-title":"Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO VigiBase report analysis","volume":"25","author":"Grouthier","year":"2020","journal-title":"Oncologist"},{"key":"B48","doi-asserted-by":"publisher","first-page":"bvab100","DOI":"10.1210\/jendso\/bvab100","article-title":"Endocrine toxicity and outcomes in patients with metastatic malignancies treated with immune checkpoint inhibitors","volume":"5","author":"Al Ashi","year":"2021","journal-title":"J Endocr Soc"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31320-5","article-title":"Type 1 diabetes","volume":"391","author":"DiMeglio","year":"2018","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0217","article-title":"Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center","volume":"3","author":"Johnson","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.05.005","article-title":"Survivorship in immune therapy: assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand","volume":"135","author":"Patrinely","year":"2020","journal-title":"Eur J Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-c and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02110","article-title":"Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial","volume":"38","author":"Eggermont","year":"2020","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-21-0123","article-title":"New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer","volume":"2022","author":"Cunha","year":"2022","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.24875\/GMM.M21000560","article-title":"Incidence and clinical characteristics of thyroid abnormalities in cancer patients treated with immune checkpoint inhibitors","volume":"157","author":"Cuenca","year":"2021","journal-title":"Gac Med Mex"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01508-5","article-title":"Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy","volume":"44","author":"Luongo","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-231236","article-title":"Nivolumab-induced hypothyroidism followed by isolated ACTH deficiency","volume":"12","author":"Martins Machado","year":"2019","journal-title":"BMJ Case Rep"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy","volume":"5","author":"Lee","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1159\/000501824","article-title":"Graves' Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature","volume":"8","author":"Brancatella","year":"2019","journal-title":"Eur Thyroid J"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081944","article-title":"Graves' disease during immune checkpoint inhibitor therapy (A case series and literature review)","volume":"13","author":"Peiffert","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B64","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12902-020-00613-5","article-title":"New-onset graves' disease after the initiation of nivolumab therapy for gastric cancer: a case report","volume":"20","author":"Yamada","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13212","article-title":"Simultaneous development of graves' disease and type 1 diabetes during anti-programmed cell death-1 therapy: a case report","volume":"11","author":"Kurihara","year":"2020","journal-title":"J Diabetes Investig"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2314032","DOI":"10.1155\/2019\/2314032","article-title":"A case report of graves' disease induced by the anti-human programmed cell death-1 monoclonal antibody pembrolizumab in a bladder cancer patient","volume":"2019","author":"Yajima","year":"2019","journal-title":"Case Rep Endocrinol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1210\/js.2017-00432","article-title":"Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J Endocr Soc"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0736-7","article-title":"Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study","volume":"122","author":"Okada","year":"2020","journal-title":"Br J Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14363","article-title":"Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors","volume":"111","author":"Kurimoto","year":"2020","journal-title":"Cancer Sci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2019.04.102","article-title":"Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer","volume":"11","author":"Koyama","year":"2019","journal-title":"J Thorac Dis"},{"key":"B72","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03151-2","article-title":"Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors","volume":"71","author":"von Itzstein","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B74","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13256-018-1708-x","article-title":"Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with hashimoto's disease and diabetes mellitus: a case report","volume":"12","author":"Yonezaki","year":"2018","journal-title":"J Med Case Rep"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-214603","article-title":"A rare case of thyroid storm","volume":"2016","author":"McMillen","year":"2016","journal-title":"BMJ Case Rep"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.2.8182","article-title":"Serum TSH, T(4), and thyroid antibodies in the united states population (1988 to 1994): national health and nutrition examination survey (NHANES III)","volume":"87","author":"Hollowell","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1977","article-title":"Thyrotropin and thyroid antibodies as predictors of hypothyroidism: a 13-year, longitudinal study of a community-based cohort using current immunoassay techniques","volume":"95","author":"Walsh","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0205","article-title":"Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American association of clinical endocrinologists and the American thyroid association","volume":"22","author":"Garber","year":"2012","journal-title":"Thyroid"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-71-3-661","article-title":"Antithyroid peroxidase autoantibodies in thyroid diseases","volume":"71","author":"Mariotti","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"B81","doi-asserted-by":"publisher","first-page":"R207","DOI":"10.1530\/EC-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review","volume":"9","author":"Stelmachowska-Bana\u015b","year":"2020","journal-title":"Endocr Connect"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0030","article-title":"Steroid treatment in the management of destructive thyrotoxicosis induced by PD1 blockade","volume":"11","author":"Brancatella","year":"2022","journal-title":"Eur Thyroid J"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0613","article-title":"The impact of high-dose glucocorticoids on the outcome of immune-checkpoint inhibitor-related thyroid disorders","volume":"7","author":"Ma","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B86","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1210\/clinem\/dgab672","article-title":"Hypophysitis, the growing spectrum of a rare pituitary disease","volume":"107","author":"Langlois","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B87","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/er.2004-0011","article-title":"Autoimmune hypophysitis","volume":"26","author":"Caturegli","year":"2005","journal-title":"Endocr Rev"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S224791","article-title":"Managing ipilimumab-induced hypophysitis: challenges and current therapeutic strategies","volume":"12","author":"Tsoli","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.836859","article-title":"Immune checkpoint inhibitor-induced hypophysitis and patterns of loss of pituitary function","volume":"12","author":"Jessel","year":"2022","journal-title":"Front Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment","volume":"14","author":"Di Dalmazi","year":"2019","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B92","doi-asserted-by":"publisher","first-page":"199","DOI":"10.18632\/oncotarget.27876","article-title":"Testosterone deficiency in men receiving immunotherapy for malignant melanoma","volume":"12","author":"Peters","year":"2021","journal-title":"Oncotarget"},{"key":"B93","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2014.0105","article-title":"Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash","volume":"12","author":"Nallapaneni","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.798517","article-title":"Immune checkpoint inhibitor-induced central diabetes insipidus: looking for the needle in the haystack or a very rare side-effect to promptly diagnose","volume":"12","author":"Barnabei","year":"2022","journal-title":"Front Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.582394","article-title":"Case report: ipilimumab-induced panhypophysitis: an infrequent occurrence and literature review","volume":"10","author":"Barnabei","year":"2020","journal-title":"Front Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-17-0146","article-title":"Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies","volume":"2018","author":"Gunawan","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01905","article-title":"Anti-PD-L1 treatment induced central diabetes insipidus","volume":"103","author":"Zhao","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B99","doi-asserted-by":"publisher","first-page":"106427","DOI":"10.1016\/j.intimp.2020.106427","article-title":"Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy","volume":"83","author":"Deligiorgi","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0334","article-title":"Anti-PD-1 treatment-induced immediate central diabetes insipidus: a case report","volume":"13","author":"Yu","year":"2021","journal-title":"Immunotherapy"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.20945\/2359-3997000000221","article-title":"Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy","volume":"64","author":"Brilli","year":"2020","journal-title":"Arch Endocrinol Metab"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.09.016","article-title":"Hypothalamitis and severe hypothalamic dysfunction associated with anti-programmed cell death ligand 1 antibody treatment","volume":"104","author":"Tshuma","year":"2018","journal-title":"Eur J Cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-021-01182-z","article-title":"Differences between immunotherapy-induced and primary hypophysitis-a multicenter retrospective study","volume":"25","author":"Amereller","year":"2022","journal-title":"Pituitary"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002493","article-title":"Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors","volume":"9","author":"Kobayashi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B105","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24898","article-title":"Quality of life, self-esteem, fatigue, and sexual function in young men after cancer: a controlled cross-sectional study","volume":"116","author":"Greenfield","year":"2010","journal-title":"Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s13539-012-0065-7","article-title":"Hypogonadism in male cancer patients","volume":"3","author":"Burney","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2021.09.011","article-title":"Secondary adrenal insufficiency: recent updates and new directions for diagnosis and management","volume":"28","author":"Gruber","year":"2022","journal-title":"Endocr Pract"},{"key":"B109","doi-asserted-by":"publisher","first-page":"19419","DOI":"10.1038\/s41598-019-56026-5","article-title":"Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French pharmacovigilance database","volume":"9","author":"Garon-Czmil","year":"2019","journal-title":"Sci Rep"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803760","article-title":"A copeptin-based approach in the diagnosis of diabetes insipidus","volume":"379","author":"Fenske","year":"2018","journal-title":"N Engl J Med"},{"key":"B111","article-title":"Diagnostic Testing for Diabetes Insipidus","volume-title":"Endotext","author":"Gubbi","year":"2000"},{"key":"B112","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s00234-018-2072-7","article-title":"Neuroimaging of central diabetes insipidus-when, how and findings","volume":"60","author":"Adams","year":"2018","journal-title":"Neuroradiology"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-Small-Cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-Small-Cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030546","article-title":"Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"12","author":"Petrelli","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B116","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1634\/theoncologist.2018-0470","article-title":"Endocrine-related adverse events related to immune checkpoint inhibitors: proposed algorithms for management","volume":"25","author":"Del Rivero","year":"2020","journal-title":"Oncologist"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-16-0108","article-title":"Hyponatraemia secondary to nivolumab-induced primary adrenal failure","volume":"2016","author":"Trainer","year":"2016","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B119","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2213-8587(13)70031-7","article-title":"Ipilimumab-induced autoimmune adrenalitis","volume":"1","author":"Min","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01845-z","article-title":"Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency: a retrospective analysis using the FAERS","volume":"45","author":"Lu","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1210\/js.2017-00170","article-title":"Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma","volume":"1","author":"Paepegaey","year":"2017","journal-title":"J Endocr Soc"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2020-0827","article-title":"Endocrine complications of immunotherapies: a review","volume":"21","author":"Hattersley","year":"2021","journal-title":"Clin Med (Lond)"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13424","article-title":"Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes","volume":"200","author":"Quandt","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00423","article-title":"Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes","volume":"104","author":"Tsang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2033-8","article-title":"Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review","volume":"66","author":"Gauci","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2518","article-title":"T-Lymphocyte infiltration to islets in the pancreas of a patient who developed type 1 diabetes after administration of immune checkpoint inhibitors","volume":"42","author":"Yoneda","year":"2019","journal-title":"Diabetes Care"},{"key":"B131","doi-asserted-by":"publisher","first-page":"8295","DOI":"10.1038\/s41598-018-26471-9","article-title":"Interferon-gamma drives programmed death-ligand 1 expression on islet \u03b2 cells to limit T cell function during autoimmune diabetes","volume":"8","author":"Osum","year":"2018","journal-title":"Sci Rep"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2018.07.006","article-title":"Expert opinion on immunotherapy induced diabetes","volume":"79","author":"Smati","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"B133","doi-asserted-by":"publisher","first-page":"8781347","DOI":"10.1155\/2019\/8781347","article-title":"Immune checkpoint inhibitor induced diabetes mellitus treated with insulin and metformin: evolution of diabetes management in the era of immunotherapy","author":"Alrifai","year":"2019","journal-title":"Case Rep Oncol Med 2019"},{"key":"B134","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12902-019-0467-z","article-title":"Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports","volume":"19","author":"Zezza","year":"2019","journal-title":"BMC Endocr Disord"},{"key":"B135","doi-asserted-by":"publisher","first-page":"S211","DOI":"10.24875\/GMM.M21000560","article-title":"Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05708-3","article-title":"Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade","volume":"65","author":"Kawada-Horitani","year":"2022","journal-title":"Diabetologia"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01151","article-title":"Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies","volume":"104","author":"Piranavan","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1039.e5","DOI":"10.1016\/j.ajem.2017.02.048","article-title":"Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism","volume":"35","author":"Win","year":"2017","journal-title":"Am J Emerg Med"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0908","article-title":"Successful treatment of immune checkpoint inhibitor-induced diabetes with infliximab","volume":"42","author":"Trinh","year":"2019","journal-title":"Diabetes Care"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocpiqo.2020.07.006","article-title":"Hypoparathyroidism: an uncommon complication associated with immune checkpoint inhibitor therapy","volume":"4","author":"El Kawkgi","year":"2020","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2009.01.001","article-title":"Anti-parathyroid and anti-calcium sensing receptor antibodies in autoimmune hypoparathyroidism","volume":"38","author":"Brown","year":"2009","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B142","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-18-0609","article-title":"Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus","volume":"180","author":"Khan","year":"2019","journal-title":"Eur J Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1157805\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T08:29:04Z","timestamp":1683793744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1157805\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":142,"alternative-id":["10.3389\/fendo.2023.1157805"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1157805","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"article-number":"1157805"}}